PharmaShots | Incisive News in 3 Shots

Subscribe Now

HCC

Innovent Publishes the Results of Sintilimab + IBI305 (bevacizumab- biosimilar) in P-II/III ORIENT-32 Study as 1L Treatment for HCC in The Lancet Oncology

Innovent Publishes the Results of Sintilimab + IBI305 (bevacizumab- biosimilar) in P-II/III ORIENT-32 Study as 1L Treatment for HC...

June 22, 2021

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)

February 21, 2019

Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

November 12, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us